Close Menu

NEW YORK (GenomeWeb) – French startup PathoQuest announced earlier this month that it has enrolled the first patient for a new cost-benefit study of its metagenomic next-generation sequencing test, iDtect, to identify pathogenic bacteria and viruses in the bloodstream of immunocompromised patients, beginning with febrile neutropenia cases.

As PathoQuest initiates the study, called IDENTIFY, in Paris, it is also eyeing the US market where it hopes to partner with laboratories to offer iDtect as a laboratory-developed test (LDT).

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.